Cite
HARVARD Citation
Torka, P. et al. (2022). Ofatumumab plus HyperCVAD/HD‐MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study. Cancer. 128 (8), pp. 1595-1604. [Online].